Structural Heart Disease

Structural heart diseases include any issues preventing normal cardiovascular function due to damage or alteration to the anatomical components of the heart. This is caused by aging, advanced atherosclerosis, calcification, tissue degeneration, congenital heart defects and heart failure. The most commonly treated areas are the heart valves, in particular the mitral and aortic valves. These can be replaced through open heart surgery or using cath lab-based transcatheter valves or repairs to eliminate regurgitation due to faulty valve leaflets. This includes transcatheter aortic valve replacement (TAVR). Other common procedures include left atrial appendage (LAA) occlusion and closing congenital holes in the heart, such as PFO and ASD. A growing area includes transcatheter mitral repair or replacement and transcatheter tricuspid valve repair and replacement.

RSS icon
Thumbnail

TEER shows potential to boost outcomes for cardiogenic shock patients

Cardiogenic shock has been linked to a heightened risk of morbidity and mortality. TEER, it seems, may be able to help provide patients with some relief. 

Thumbnail

How diabetes impacts TEER outcomes

The new analysis, published in JACC: Heart Failure, focused on patient data from the renowned COAPT trial. 

Confirmed: Watchman FLX LAAC device safe for nonvalvular AFib patients

New two-year findings, presented at TVT 2021, suggest that the Watchman FLX device is a safe alternative to long-term oral anticoagulation therapy.

TAVR outcomes similar after 1 year in low-risk bicuspid, tricuspid aortic stenosis patients

Lead author John Forrest, MD, a cardiologist at Yale School of Medicine, presented the findings at TVT 2021. He noted that it felt great to finally return to in-person conferences after COVID kept people at home for so long. 

Device-related thrombus after LAAO tied to ischemic events

Discharge medications after LAAO made no impact on the presence of device-related thrombus, researchers found.

Thumbnail

DOACs outperform VKAs when TAVR patients require oral anticoagulation

Hoping to shed new light on the debate between DOACs and VKAs, researchers in France examined data from more than 24,000 TAVR patients.

3-in-1 transseptal introducer system receives FDA approval

The 3-in-1 offering includes an introducer sheath, positioning balloon and RF puncture dilator.

Thumbnail

Aortic stenosis most common in white and Hispanic adults

A team of cardiologists evaluated echocardiography data from more than 3,000 U.S. patients.

Displaying 577 - 584 of 879
Design by Adaptive Theme